What is ANVS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ANVS?

P/E (TTM) is n/a and 52-week range is $1.04 to $5.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ANVS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ANVS?

The company profile lists net income (TTM) near $-62M, EPS (TTM) near $-1.78 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Annovis Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Malvern, Pennsylvania, US, 34.6M shares outstanding, ISIN US03615A1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Annovis Bio Inc

$ANVS

Health Care · Biotechnology

IR Run Scenarios

$1.21

+3.42%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Employees

Website

www.annovisbio.com/

IPO

2020-01-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)